NNVC
NanoViricides, Inc.
Biotechnology
Market Cap$31M
5Y Perf.-81.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NNVC vs COCP
Revenue, margins, valuation, and 5-year total return — side by side.
COCP
Cocrystal Pharma, Inc.
Biotechnology
Market Cap$18M
5Y Perf.-88.1%
NNVC vs COCP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NNVC | COCP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $31M | $18M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-2.22T | $-10M |
| Total Debt | $0.00 | $2M |
| Cash & Equiv. | $2M | $10M |
NNVC vs COCP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NNVC
COCP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| NanoViricides, Inc. (NNVC) | 100 | 18.9 | -81.1% |
| Cocrystal Pharma, I… (COCP) | 100 | 11.9 | -88.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NNVC vs COCP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NNVC leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Cocrystal Pharma, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
NNVC
NanoViricides, Inc.
The Income Pick
NNVC carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 1.34
- -95.5% 10Y total return vs COCP's -99.4%
- Lower volatility, beta 1.34, current ratio 1.28x
Best for: income & stability and long-term compounding
COCP
Cocrystal Pharma, Inc.
The Growth Play
COCP is the clearest fit if your priority is growth exposure.
- EPS growth 49.2%
- 48.4% revenue growth vs NNVC's -258K%
- 4.0% margin vs NNVC's 1.4%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | COCP | 48.4% revenue growth vs NNVC's -258K% |
| Quality / Margins | COCP | 4.0% margin vs NNVC's 1.4% |
| Stability / Safety | NNVC | Beta 1.34 vs COCP's 1.36 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NNVC | +14.5% vs COCP's -11.5% |
| Efficiency (ROA) | NNVC | -18.1% ROA vs COCP's -92.6%, ROIC -114.0% vs -8.0% |
NNVC vs COCP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNNVCLAGGINGCOCP
COCPCocrystal Pharma, Inc.
1leads
NNVCNanoViricides, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs COCPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
COCP1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NNVC4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
NNVC5/6
Risk & VolatilityBeta, volatility, and downside exposure
NNVC2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
COCP leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NNVC and COCP operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NNVCNanoViricides, In… | COCPCocrystal Pharma,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$10M |
| Net IncomeAfter-tax profit | -$2.22T | -$10M |
| Free Cash FlowCash after capex | -$3.73T | -$10M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +21.4% | +61.2% |
COCP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NNVC and COCP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NNVCNanoViricides, In… | COCPCocrystal Pharma,… |
|---|---|---|
| Market CapShares × price | $31M | $18M |
| Enterprise ValueMkt cap + debt − cash | $29M | $10M |
| Trailing P/EPrice ÷ TTM EPS | -2.25x | -0.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.86x | 1.49x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NNVC and COCP each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NNVC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
NNVC delivers a -20.1% return on equity — every $100 of shareholder capital generates $-20 in annual profit, vs $-126 for COCP.
| Metric | NNVCNanoViricides, In… | COCPCocrystal Pharma,… |
|---|---|---|
| ROE (TTM)Return on equity | -20.1% | -126.1% |
| ROA (TTM)Return on assets | -18.1% | -92.6% |
| ROICReturn on invested capital | -114.0% | -8.0% |
| ROCEReturn on capital employed | -101.1% | -91.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | — | 0.19x |
| Net DebtTotal debt minus cash | -$2M | -$8M |
| Cash & Equiv.Liquid assets | $2M | $10M |
| Total DebtShort + long-term debt | $0 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
NNVC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
NNVC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NNVC five years ago would be worth $3,912 today (with dividends reinvested), compared to $878 for COCP. Over the past 12 months, NNVC leads with a +14.5% total return vs COCP's -11.5%. The 3-year compound annual growth rate (CAGR) favors NNVC at 3.5% vs COCP's -20.4% — a key indicator of consistent wealth creation.
| Metric | NNVCNanoViricides, In… | COCPCocrystal Pharma,… |
|---|---|---|
| YTD ReturnYear-to-date | +17.4% | +40.4% |
| 1-Year ReturnPast 12 months | +14.5% | -11.5% |
| 3-Year ReturnCumulative with dividends | +10.9% | -49.6% |
| 5-Year ReturnCumulative with dividends | -60.9% | -91.2% |
| 10-Year ReturnCumulative with dividends | -95.5% | -99.4% |
| CAGR (3Y)Annualised 3-year return | +3.5% | -20.4% |
NNVC leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
NNVC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NNVC is the less volatile stock with a 1.34 beta — it tends to amplify market swings less than COCP's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NNVC currently trades 63.7% from its 52-week high vs COCP's 52.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NNVCNanoViricides, In… | COCPCocrystal Pharma,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 1.36x |
| 52-Week HighHighest price in past year | $2.23 | $2.67 |
| 52-Week LowLowest price in past year | $0.85 | $0.86 |
| % of 52W HighCurrent price vs 52-week peak | +63.7% | +52.1% |
| RSI (14)Momentum oscillator 0–100 | 67.0 | 54.0 |
| Avg Volume (50D)Average daily shares traded | 249K | 2.9M |
NNVC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NNVCNanoViricides, In… | COCPCocrystal Pharma,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NNVC leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). COCP leads in 1 (Income & Cash Flow). 1 tied.
Best OverallNanoViricides, Inc. (NNVC)Leads 3 of 6 categories
Loading custom metrics...
NNVC vs COCP: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — NNVC or COCP?
Over the past 5 years, NanoViricides, Inc.
(NNVC) delivered a total return of -60. 9%, compared to -91. 2% for Cocrystal Pharma, Inc. (COCP). Over 10 years, the gap is even starker: NNVC returned -95. 5% versus COCP's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NNVC or COCP?
By beta (market sensitivity over 5 years), NanoViricides, Inc.
(NNVC) is the lower-risk stock at 1. 34β versus Cocrystal Pharma, Inc. 's 1. 36β — meaning COCP is approximately 2% more volatile than NNVC relative to the S&P 500.
03Which has better profit margins — NNVC or COCP?
NanoViricides, Inc.
(NNVC) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cocrystal Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NNVC leads at 0. 0% versus 0. 0% for COCP. At the gross margin level — before operating expenses — NNVC leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — NNVC or COCP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is NNVC or COCP better for a retirement portfolio?
For long-horizon retirement investors, NanoViricides, Inc.
(NNVC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (NNVC: -95. 5%, COCP: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between NNVC and COCP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.